Standardizing the effective correlated dosage of olanzapine and empagli-flozin in female Wistar rats

Aim The primary aim of this study was to standardize the correlated effective dosage of an antidiabetic drug empagliflozin (EMPA) mediated reversal of body weight gain (BWG) induced by olanzapine (Ola), an antipsychotic drug. Background Atypical antipsychotics are associated with BWG and metabolic disturbances for which many approaches have been used to minimize these issues, including antidiabetic drugs. The antidiabetic drugs have been quite effective in reversing BWG induced by the ad-ministration of antipsychotic drugs in patients who have psychosis, schizophrenia and bipolar disorder. Objective The objective of this study was to standardize the correlated effective dosage of EMPA mediated reversal of BWG induced by Ola. Method The study was carried out for 28 days to represent the chronic effect of Ola on female Wistar rats. Rats were divided into three groups based on the dose they received: control (vehicle), Ola-4 and Ola-8 (4 and 8 mg/kg/OD, respectively), and EMPA-10 and EMPA-20 (10 and 20 mg/kg/OD, respectively). Results Both doses of Ola produced a significant increase in the percentage of BWG, however Ola-4 produced a higher BWG. Also, both the doses of EMPA were able to reverse the effect of Ola-induced BWG, however, EMPA-20 has produced higher reversal in BWG and normalized the rat's body weight. Conclusion We conclude that Ola-4 and EMPA-20 were the most effective dosage for experimental purposes in female Wistar rats. The findings of this study standardized the effective correlated dosage of olanzapine and empagliflozin in female Wistar rats that will help un-derstand the underlying molecular and behavioral mechanisms.